Cargando…
Aptamers as Smart Ligands for Targeted Drug Delivery in Cancer Therapy
Undesirable side effects and multidrug tolerance are the main holdbacks to the treatment of cancer in conventional chemotherapy. Fortunately, targeted drug delivery can improve the enrichment of drugs at the target site and reduce toxicity to normal tissues and cells. A targeted drug delivery system...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781707/ https://www.ncbi.nlm.nih.gov/pubmed/36559056 http://dx.doi.org/10.3390/pharmaceutics14122561 |
_version_ | 1784857140261814272 |
---|---|
author | Wei, Zongyi Zhou, Yuxin Wang, Rongjie Wang, Jin Chen, Zhenhua |
author_facet | Wei, Zongyi Zhou, Yuxin Wang, Rongjie Wang, Jin Chen, Zhenhua |
author_sort | Wei, Zongyi |
collection | PubMed |
description | Undesirable side effects and multidrug tolerance are the main holdbacks to the treatment of cancer in conventional chemotherapy. Fortunately, targeted drug delivery can improve the enrichment of drugs at the target site and reduce toxicity to normal tissues and cells. A targeted drug delivery system is usually composed of a nanocarrier and a targeting component. The targeting component is called a “ligand”. Aptamers have high target affinity and specificity, which are identified as attractive and promising ligands. Therefore, aptamers have potential application in the development of smart targeting systems. For instance, aptamers are able to efficiently recognize tumor markers such as nucleolin, mucin, and epidermal growth factor receptor (EGFR). Besides, aptamers can also identify glycoproteins on the surface of tumor cells. Thus, the aptamer-mediated targeted drug delivery system has received extensive attention in the application of cancer therapy. This article reviews the application of aptamers as smart ligands for targeted drug delivery in cancer therapy. Special interest is focused on aptamers as smart ligands, aptamer-conjugated nanocarriers, aptamer targeting strategy for tumor microenvironment (TME), and aptamers that are specified to crucial cancer biomarkers for targeted drug delivery. |
format | Online Article Text |
id | pubmed-9781707 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97817072022-12-24 Aptamers as Smart Ligands for Targeted Drug Delivery in Cancer Therapy Wei, Zongyi Zhou, Yuxin Wang, Rongjie Wang, Jin Chen, Zhenhua Pharmaceutics Review Undesirable side effects and multidrug tolerance are the main holdbacks to the treatment of cancer in conventional chemotherapy. Fortunately, targeted drug delivery can improve the enrichment of drugs at the target site and reduce toxicity to normal tissues and cells. A targeted drug delivery system is usually composed of a nanocarrier and a targeting component. The targeting component is called a “ligand”. Aptamers have high target affinity and specificity, which are identified as attractive and promising ligands. Therefore, aptamers have potential application in the development of smart targeting systems. For instance, aptamers are able to efficiently recognize tumor markers such as nucleolin, mucin, and epidermal growth factor receptor (EGFR). Besides, aptamers can also identify glycoproteins on the surface of tumor cells. Thus, the aptamer-mediated targeted drug delivery system has received extensive attention in the application of cancer therapy. This article reviews the application of aptamers as smart ligands for targeted drug delivery in cancer therapy. Special interest is focused on aptamers as smart ligands, aptamer-conjugated nanocarriers, aptamer targeting strategy for tumor microenvironment (TME), and aptamers that are specified to crucial cancer biomarkers for targeted drug delivery. MDPI 2022-11-22 /pmc/articles/PMC9781707/ /pubmed/36559056 http://dx.doi.org/10.3390/pharmaceutics14122561 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Wei, Zongyi Zhou, Yuxin Wang, Rongjie Wang, Jin Chen, Zhenhua Aptamers as Smart Ligands for Targeted Drug Delivery in Cancer Therapy |
title | Aptamers as Smart Ligands for Targeted Drug Delivery in Cancer Therapy |
title_full | Aptamers as Smart Ligands for Targeted Drug Delivery in Cancer Therapy |
title_fullStr | Aptamers as Smart Ligands for Targeted Drug Delivery in Cancer Therapy |
title_full_unstemmed | Aptamers as Smart Ligands for Targeted Drug Delivery in Cancer Therapy |
title_short | Aptamers as Smart Ligands for Targeted Drug Delivery in Cancer Therapy |
title_sort | aptamers as smart ligands for targeted drug delivery in cancer therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781707/ https://www.ncbi.nlm.nih.gov/pubmed/36559056 http://dx.doi.org/10.3390/pharmaceutics14122561 |
work_keys_str_mv | AT weizongyi aptamersassmartligandsfortargeteddrugdeliveryincancertherapy AT zhouyuxin aptamersassmartligandsfortargeteddrugdeliveryincancertherapy AT wangrongjie aptamersassmartligandsfortargeteddrugdeliveryincancertherapy AT wangjin aptamersassmartligandsfortargeteddrugdeliveryincancertherapy AT chenzhenhua aptamersassmartligandsfortargeteddrugdeliveryincancertherapy |